High Note Wealth LLC Has $878,000 Stock Holdings in Johnson & Johnson $JNJ

High Note Wealth LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 19.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,750 shares of the company’s stock after buying an additional 940 shares during the quarter. High Note Wealth LLC’s holdings in Johnson & Johnson were worth $878,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Global Strategic Investment Solutions LLC raised its stake in shares of Johnson & Johnson by 3.5% in the 2nd quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock valued at $294,000 after purchasing an additional 65 shares during the period. JSF Financial LLC raised its stake in shares of Johnson & Johnson by 2.2% in the 2nd quarter. JSF Financial LLC now owns 2,993 shares of the company’s stock valued at $457,000 after purchasing an additional 65 shares during the period. Elios Financial Group Inc. raised its stake in shares of Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock valued at $746,000 after purchasing an additional 66 shares during the period. Atlantic Family Wealth LLC raised its stake in shares of Johnson & Johnson by 4.4% in the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock valued at $266,000 after purchasing an additional 67 shares during the period. Finally, MBA Advisors LLC raised its stake in shares of Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock valued at $921,000 after purchasing an additional 68 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 0.5%

Shares of NYSE:JNJ opened at $189.75 on Thursday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $190.22. The stock has a market cap of $456.98 billion, a PE ratio of 20.29, a P/E/G ratio of 2.41 and a beta of 0.40. The business has a 50 day moving average of $177.49 and a 200-day moving average of $163.37. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the previous year, the company posted $2.82 earnings per share. The business’s revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Weiss Ratings raised Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Royal Bank Of Canada raised their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a report on Friday, October 3rd. Bank of America raised their price objective on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Barclays lifted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $189.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.